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In 1987, a group infection of hepatitis in patients receiving a contaminated fibrinogen product was first reported to
the Japanese regulatory agency. Eventually, this serious drug incident involved more than 10,000 cases of infection.
In response, the Government of Japan established a responding inspection committee in 2008 to make
recommendations for the restructuring of drug regulatory administration. The final report was issued in 2010. One
agenda item of this restructuring was the improvement of drug-related safety risk communications. Our research
group on drug safety risk communications, which is funded by the Government of Japan, surveyed pharmaceutical
companies regarding their perspective on current risk communications. The survey was conducted using an anonymous
questionnaire developed for this study which included the three operational domains of targets, contents, and measures
of drug risk communication. Fifty-two of the 74 member companies of the Post-marketing Surveillance Subcommittee of
the Japan Pharmaceutical Manufacturer’s Association participated, and this response rate of more than 70% was
considered sufficient to ensure the external validity of the survey results. Results showed that the most highly
prioritized aspect of risk messaging was the strength of evidence, and that outcome evaluation of risk communication
gained recognition. Further, while physicians and pharmacists were the most prioritized communication targets,
pharmacovigilance departments devoted the most resources to regulators, at more than 30%. The Internet was
recognized as a useful public source of risk information, whereas Drug Guides for Patients delivered on the web
were considered under-recognized. Further discussion of these results with the aim of enhancing the restructuring
of the Japanese drug regulatory administration system are warranted.
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Safety issues related to medical products have serious and
significant implications not only for individual health, but
occasionally also for public health on a large scale. Given
the inherently uncertain safety and effectiveness of medi-
cinal products, discussions of the importance and signifi-
cance of benefit/risk communications with healthcare
professionals and patients have been repeated, not only in
the wake of particular drug disasters but on a routine basis
(Bahri and Harrison-Woolrych 2012a, 2012b; Avorn 2008;
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The Erice Declaration on Communicating Drug Safety
Information in September 1997 asserted that risk commu-
nication is a public health activity which depends on the
collective responsibility of all parties, involving patients
and healthcare professionals, as well as multiple other
stakeholders, including pharmaceutical companies, drug
regulators, academia, researchers, media and others (The
Uppsala Monitoring Centre 1997).
Pharmaceutical industries play a significant role in the
safety risk communication of their medicinal products.
They are the upstream supplier of information related to
medicinal products, and at the same time the product
supplier also. They are legally bound and socially re-
sponsible for the collection and evaluation of informa-
tion related to the effectiveness, safety and rational use
of medicinal products before and after market launch,is an open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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information to healthcare professionals and patients,
with the aim of optimizing the benefit-risk balance in
the real world. Pharmaceutical companies consequently
possess the most abundant information regarding the ef-
ficacy and safety of their products, and multiple commu-
nication techniques and channels, albeit that these are
under strict regulatory supervision. In this communica-
tion flow, safety risk information for drugs sourced from
pharmaceutical companies streams down to concerned
regulators, healthcare professionals, patients and other
parties of interest. Discussion primarily occurs between
regulatory agencies and pharmaceutical companies to
determine how, to whom, and by what measures safety
risk information should be communicated. Despite strong
recommendations for the tailoring of communications to-
ward specific targets, however, there is scant opportunity
for lay people, patients and practitioners to be involved in
this discussion (Bahri and Harrison-Woolrych 2012b;
European Medicines Agency 2013; Bahri 2010). Addition-
ally, despite the fact that drugs require administration into
patients’ bodies under the direction of practitioners to
exert their efficacy, transparency is somewhat compro-
mised for both patients and healthcare professionals with
regard to the discussion over which risk information for
medicinal products should be made publicly available, and
when this information should be communicated, which in
turn leads to public distrust to pharmaceutical companies
(Olsen and Whalen 2009). The necessity of systematic in-
vestigation of safety risk communications carried out as
part of the pharmacovigilance activities of pharmaceutical
companies has long been recognized, but the number of
reports appearing to date is markedly low (Giampaolo
2010; Ingate et al. 2006).
In the aftermath of a catastrophic drug disaster in Japan
in which more than 10,000 patients treated with contami-
nated pharmaceutical products of fibrinogen and coagula-
tion factor IX were infected with viral hepatitis (Horiuchi
et al. 2009), the investigating committee’s final report in
2010 offered recommendations requiring the restructuring
of the entire regulatory system for pharmaceutical
products (Committee on Regulatory Restructuring for
Inspection and Recurrence Prevention of Drug-Induced
Hepatitis Disaster Case 2010). This report proposed the
mobilization of information technology and involvement
of patients in improved communications for drug safety
within the Japanese post-marketing pharmacovigilance
system.
In the present study, this government-funded research
group on drug safety risk communication surveyed pharma-
ceutical companies for their views and perspectives on safety
risk communication in Japan. The findings were ex-
pected to serve as a basis for ongoing discussion on
this restructuring.Methods
Study design
A questionnaire survey was conducted among persons in
charge of the pharmacovigilance departments of member
companies of the Japan Pharmaceutical Manufacturer’s
Association (JPMA). The JPMA is the major industry as-
sociation for pharmaceutical companies located in Japan,
and all companies involved in the research and develop-
ment of new medicinal products for human treatment
and diagnosis are members.
Survey questionnaire development
An anonymous, self-administered questionnaire was de-
veloped by a multidisciplinary study panel consisting of
physicians, epidemiologists, a media expert, and a phar-
macoepidemiologist with business experience in phar-
macovigilance activities at a pharmaceutical company. In
this survey, safety risk communication was defined as
the exchange of drug information regarding safety risks
by pharmaceutical companies with the aim of ensuring
the rational use of drugs in practical clinical settings.
Three operational domains related to safety risk commu-
nication were identified, namely contents, targets, and
measures, and question items for each were developed
by expert discussion. The questionnaire also enquired
about background information of companies and respon-
dents. The draft questionnaire was reviewed for face and
content validities before finalization by an independent se-
nior pharmacovigilance executive at a pharmaceutical
company, and by the chairman of the Post-Marketing
Surveillance (PMS) Subcommittee of the Drug Evaluation
Committee of the JPMA. The final contents of the survey
questionnaire were also reviewed and approved by the
Subcommittee Chairman and by the Subcommittee Secre-
tariat Officer regarding the protection of anonymity and
confidentiality (Additional file 1).
Questionnaire items
The contents domain included three items. The first
item assessed the prioritization of eight important as-
pects of risk information, known as the Media Doctor
Australia rating criteria for the adverse effects of media
coverage of new medical treatments (Additional file 2)
(Media Doctor Australia 2012). The other two items
were open questions which asked about what factors are
taken into consideration during the creation and convey-
ance of risk communication messages. The targets domain
included three items regarding eight communication tar-
gets, namely patients, the public, physicians, pharmacists,
paramedics, regulators, the media, and in-company divi-
sions as reference. The evaluation included the relative
importance of target audience and the degree of success
of communication with the target audience. Further, re-
spondents were also asked to estimate workload allocation
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igilance department. The measures domain included 10
items. Drug Guides for Patients (DGPs) are created by the
market authorization holders of drugs for three types of
drugs, namely those with a Warning section in the pack-
age insert; those with a package insert requiring specific
instructions to patients to prevent serious adverse drug re-
actions; and those requiring the provision of specific infor-
mation to patients to ensure rational use, excluding drugs
used for tests and surgeries (Pharmaceuticals and Food
Safety Bureau 2005). This requirement for DGPs is similar
to that for the Medication Guides prepared as a part of
the US Risk Evaluation and Mitigation Systems (REMS)
(The US Food and Drug Administration 2011). The DGPs
were assessed according to the 10 rating criteria used in a
survey of US Food and Drug Administration (FDA) publi-
cations on the internet conducted by the Center for Drug
Evaluation and Research (CDER) (The US Food and Drug
Administration 2009). Items included “easy to read”, “easy
to find what I need”, “organization of information”, “font
and font size”, “length”, “relevance to your specialty or
area of expertise”, “understandable”, “timeliness”, “helpful”,
and “amount of background information”. Rating was done
on 5-point Likert scales from poor through average to ex-
cellent, with 3 as the mid-point and higher scores indicat-
ing a better result. Two items asked respondents to assess
internet websites providing drug information which were
operated by pharmaceutical companies themselves with re-
gard to their usefulness for risk communications to pa-
tients and healthcare professionals. Further, respondents
were also asked to choose the three most useful measures
for risk communications in emergencies from among regu-
latory measures, including a DHCP letter and revision of
the package insert; direct communication by the regulatory
authority; communication by company medical representa-
tives; publication via mass media or academic journals; and
communication via company websites. They were also
asked to rank these measures for effectiveness from first to
third rank, with the first-ranked measure given a score of
three and the third-ranked a score of one, while measures
which were not selected were scored as zero. Last, we soli-
cited opinions about disclosure of the risk management
plan, for which a new local regulatory guidance had been
issued (April 2012) but which had yet to be implemented
at the time of survey (Pharmaceuticals and Food Safety
Bureau 2012).
Study procedure and analysis
Agreement on the objectives and protocol procedures was
obtained from the JPMA PMS Subcommittee during
study planning. The JPMA PMS Subcommittee office then
sent the questionnaires with cover letters requesting par-
ticipation via the postal service in mid-February 2011 to
its 74 subcommittee member companies, independentlyfrom the study team to maintain survey respondent ano-
nymity. The cover letter explained the outlines and objec-
tives of the study, and mentioned the protection of
respondent anonymity and confidentiality in disclosure to
academic publications. Further, we asked that the re-
spondent to the questionnaire should be a permanent em-
ployee(s) who was engaged in pharmacovigilance activities
and was capable of representing the responding company’s
opinions. The JPMA PMS Subcommittee office sent two
reminder e-mails to the addressees, at the time the ques-
tionnaire was sent and 2 months later. The completed
questionnaires were returned by postal mail directly to the
study team. “No response” to a questionnaire item were
excluded from the analysis, except for background in-
formation. The responses were summarized with de-
scriptive statistics using SPSS ver 19 (IBM Corp., Armonk,
NY, USA).
Results
Fifty-two questionnaires were collected between mid-
February 2011 and the end of April 2011 (return rate:
70.3%). After exclusion of one questionnaire which had
more than half of its items unanswered, 51 question-
naires were eligible for analysis, of which 12 were from
foreign capital companies (23.5%) and 34 from large-
scale companies with more than a thousand permanent
employees (66.7%). In 92.2% of the responding compan-
ies, employees engaged in pharmacovigilance activities
accounted for fewer than 10% of all permanent em-
ployees. Forty-one respondents were supervisors (80.4%),
and more than half were aged in their 50s (51.0%),
followed by those in their 40 s (41.2%). Years of experi-
ence in post-marketing pharmacovigilance activities ranged
1 to 35, with a median of 11. Nineteen were the designated
safety management supervisor under the Japanese Good
Vigilance Practice Ministry Ordinance.
Contents
The relative importance of eight aspects in the transmis-
sion of messages for risk information, which is known as
the Media Doctor Australia rating criteria for adverse ef-
fects, was rated (Figure 1). Seventeen respondents ranked
‘evidence (mention of strength of evidence and correct in-
terpretation)’ as the first-ranked aspect, followed by ‘strati-
fication of patients with regard to harm (mentions which
groups of patients are most likely to be harmed)’ and
‘number of people affected by harm (some quantification
of the number of people or percent of people affected by
the harm)’, with the total of the above three aspects ac-
counting for approximately one-half of the first through
fourth ranks. Less importance was given to the other as-
pects, with ‘treatment option’ assigned the lowest import-
ance. When respondents were asked about what they
paid attention to when creating messages for risk
Figure 1 Prioritization of aspects according to the criteria of Media Doctor Australia in risk communication messages for
pharmaceutical products by pharmacovigilance staff at drug companies. Evidence: Where relevant there is mention of the strength of
evidence and correct interpretation. Stratification of patients with regard to harm: Mentions which groups of patients are most likely to be
harmed. Number of people affected by harm: Some quantification of the number of people or percent of people affected by the harm. Novelty
of harm: Mentions whether or not the harm was previously identified or mentions what is added to previous knowledge about it. Quantification
of harms: Some quantification of harm in terms of severity. Benefit to harm ratio: Tries to balance reporting of both benefits and harms or gives
some sense of the ratio between the two. Sources of information: Provides details on information sources and their potential COI, and reports
independent source or mentions unsuccessful attempts to obtain corroboration. Treatment options: Mentions alternatives and discusses whether
alternatives are more or less harmful. Each criterion was rated from first to eighth according to its importance in transmitting risk information.
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eration to the comprehensibility of contents, while 12
others focused on the prevention of health hazard as
an outcome of risk communication. When asked what
they would pay attention to in transmitting risk messages,
16 respondents answered the promptness of communica-
tion and 10 answered the medium used for communica-
tion. Four respondents emphasized the importance of
behavioral changes as an outcome of message transmis-
sions with the intention of risk minimization.
Targets
Relative importance of the eight communication targets
was rated (Figure 2). Physicians were ranked first by 31
respondents. Pharmacists were not ranked first by any
respondent but were ranked second by 27 respondents;
patients were ranked first by 8 respondents, second by 4,
and third by 10; paramedics were ranked third by 14 re-
spondents; and the regulatory authority was ranked
fourth by 14. The public and media ranked lower than
in-company divisions. The degree of subjective success
in risk communication was assessed for each of the
above communication parties (Figure 3). Risk communi-
cation with the regulatory agency was rated as most suc-
cessful among the parties (‘fairly successful’ or above:
100%), followed by pharmacists and physicians (both98.0%); whereas paramedics (76.0%), patients (61.7%),
the media (53.1%) and the public (31.1%) were rated
lower than in-company divisions (87.8%). Pharmacovigi-
lance departments allocated the greatest time resources
to the regulatory agency (mean 31.4%), followed by phy-
sicians (24.9%) and pharmacists (14.7%, Figure 4). The
rough estimation of work-time allocation to paramedics
(5.0%), patients (4.8%), the public (1.9%), and the media
(1.6%) were smaller than that for in-company divisions
(13.0%).
Measures
Forty-three respondents had experience in the creation of
DGPs (84.3%). These were rated good for “font and font
size” (mean score: 3.9), “helpful” (3.6), and “organization
of information” (3.6), and 70% of the respondents evalu-
ated them as useful for patients (Figure 5). However, nine
respondents commented that DGPs are likely not utilized
effectively by patients due to their low recognition among
the public. Some commented that since all package inserts
and corresponding DGPs are now accessible via the same
PMDA homepage, the purpose and significance of DGPs,
whose source information is encompassed in the package
inserts, were questionable. 62.0% of respondents answered
that it was useful to create a DGP for all newly approved
drugs, particularly to ensure the disclosure of information,
Figure 2 Prioritization of target audiences by pharmacovigilance staff at pharmaceutical companies in safety risk communication for
pharmaceutical products. Respondents rated these criteria from first to eighth according to their importance as a target for risk communications.
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sufficient to prepare a DGP for medicines requiring par-
ticular attention in use by patients and are administered
by patients themselves, in line with the current regula-
tions. New development of an additional tool for patients
regarding revision of the ‘Precautions’ section of package
inserts was considered unnecessary by more respondents
(30.6%) than those who considered it necessary (24.5%). AFigure 3 Evaluation of success by pharmacovigilance staff at pharma
concerned parties.respondent commented that such revisions should be in-
corporated into the DGP in order to preserve a single
communication tool for patients.
62.0% of respondents assessed the websites run by
pharmaceutical companies as effective for risk communi-
cation with patients and 76.0% assessed them as effective
for risk communication with healthcare professionals, in
contrast to low marks for usability given to the PMDAceutical companies concerning risk communications with
Figure 4 Estimates of work-time allocation according to communication target by the pharmacovigilance departments of pharmaceutical
companies. Presented in mean± SD.
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websites included their rich contents and customizable de-
sign fitted for the purpose and intention of the companies,
as well as their openness, easy and quick access, and inter-
activity. Major concerns were expressed regarding the lim-
ited range of patients with the tools and ability to access
these sites, the varying levels of literacy among patients,
biased or partial contents provided on these sites, and con-
cerns related to the use of internet websites arising from
the present legal prohibition against direct-to-consumer ad-
vertising for drugs. Of note, a few respondents commentedFigure 5 Evaluation of Drug Guide for Patients by pharmacovigilancethat these sites provide an alternative, out-of-office hours
communication tool for healthcare professionals, by
complementing the office hour activities of medical
representatives.
The respondents assessed the effectiveness of the eight
channels for communicating risk information in emergency
situations. Regulatory measures such as Dear Healthcare
Professional letters and revisions of the package insert, dir-
ect communication by the regulatory authority, and com-
munication by company medical representatives were rated
as most effective (mean rating ± SD: 1.5 ± 1.1, 1.5 ± 1.2,staff at pharmaceutical companies (n = 52).
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the media (0.9 ± 1.1) and communication via company
websites (0.4 ± 0.8).
67.3% of respondents considered that disclosure of the
safety risk management plan was useful, with the expect-
ation that this would make it easier to gain the cooper-
ation of healthcare professionals and patients in ensuring
effective implementation, and by reason of the public sig-
nificance of ensuring the transparency of post-marketing
activities. Concern was expressed over the potential of ex-
plicit scientific language to provoke unnecessary misun-
derstanding and unrest among patients, and over the need
to tailor the language in such disclosures for lay people.Other comments
Among the numerous comments, notable responses in-
cluded the need to establish a single integrated mechan-
ism to communicate drug information to healthcare
professionals and patients; the need to consider benefit-
risk balance and the accurate comprehension of risks
during risk communication; the expectation that the
media should be a responsible party not only in always-
negative but also positive involvement with responsibility
in public risk communication; and the need for official
guidelines and a regulatory department specialized in
direct communications with healthcare professionals,
taking into account the seriousness of the risk.Discussion
Here, we comprehensively investigated drug company
perspectives on current risk communications for drug
safety. To our knowledge, this is the first such study
conducted in Japan.
The response ratio of 70% was considered sufficient to
ensure the external validity of the survey results, and
was additionally strengthened by the following consider-
ations. More than 10 of the targeted companies are con-
sidered to be currently inactive or to have reduced post-
marketing pharmacovigilance activities because their
products are generic, legacy, or licensed out to other
companies, and accordingly might not have responded
to the survey. Foreign capital companies account for
25.6% of all member companies of the JPMA (Japan
Pharmaceutical Manufacturers Association 2013), which
is consistent with the ratio of domestic to foreign capital
among the firms responding to this survey. Responses
were predominately from large-scale companies with
more than one thousand regular employees, which ac-
count for the majority of pharmaceutical companies sell-
ing newly developed pharmaceutical products in Japan.
Many respondents appeared to be sufficiently experi-
enced in the area of pharmacovigilance to provide ad-
equate answers.Contents
To be successful, messages for risk communications need
to convey a balance of multiple conflicting requirements:
they need to be written in a clear, simple and comprehen-
sive manner on topics that are relevant and important,
and yet at the same time they need to be brief (Seligman
and Osborne 2009; Mazor et al. 2005). We found that
many companies prioritized the strength of evidence and
place a high value on comprehension, probably because of
their intent to ensure the credibility of the message. This
appears to reflect the principle that the effectiveness of
risk communication depends on the creditability of the
message (Bahri and Harrison-Woolrych 2012b). Aspects
at the next ranking level, ‘Stratification of patients with re-
gard to harm’ and ‘Number of people affected by harm’,
likely include the expectation of behavioral changes in
medical practice as a consequence of the communication.
This question lacked an option of ‘mention of what
should be done differently’ since the Media Doctor rating
criteria lack it; nevertheless, the comments of several re-
spondents regarding the question on the creation of mes-
sages emphasized the importance of the outcome of
message transmission, indicating that pharmaceutical
companies are likely to next focus on the effectiveness of
message transmission. The EU and US guidelines clearly
recommend that communication plans include the assess-
ment of effectiveness, such as quantification of behavioral
changes, survey of comprehension, and reductions in ad-
verse event reporting (Edwards and Chakraborty 2012;
The US Food and Drug Administration 2009; European
Medicines Agency 2013). The Japanese regulations for the
provision of DHCP letters, in contrast, requires a pharma-
ceutical company to assesses only the distribution of the
communication materials to medical institutions and
practitioners in the communication plan. Unlike the EU
and US plans, therefore, the Japanese communication plan
does not address ‘true effectiveness’ (Pharmaceuticals and
Food Safety Bureau 2011a). The introduction of risk man-
agement planning in Japan, although delayed until April
2013, urges the Japanese regulatory community to change
the poor methodology of the current method of assessing
communication practices (Pharmaceuticals and Food
Safety Bureau 2012).
Targets
Stakeholders and the message to be communicated in
risk communications vary depending on the type of
harm/risk. Communication with the most prioritized tar-
gets, physicians and pharmacists, was considered mostly
successful, indicating that drug companies focused in-
tensively on these two occupations, as evidenced by the
considerable time allocated to them shown in the other
question item. Patients were rated as third; however, risk
communication with patients was rated as less successful
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survey. Drug companies in Japan communicate with pa-
tients in an indirect and unidirectional fashion via
healthcare professionals, patient-oriented handouts, and
corporate websites. Direct-to-consumer advertisements
are legally prohibited, and drug company activities and
publications directed to patients are strictly regulated.
Given the comparatively small work-time allocation to
patients, the high prioritization given to patients as
communication targets in this survey therefore likely
represents corporate policies and conceptual but un-
substantial patient-oriented attitudes.
We found the lower ranking of the regulatory author-
ity as a communication target to be inconsistent with
the finding that the regulatory authority received the lar-
gest work-time allocation. Pharmaceutical companies are
required to consult the regulatory authority when com-
mencing regulatory actions involving risk communica-
tion activities which target healthcare professionals and
the public. We speculate that the drug companies may
be concerned about being seen as excessively authority-
oriented, with a view to subsequent publication of the
survey results. Additionally, risk communications with the
regulatory authority were all rated successful or better.
We speculate that respondents might have censored their
responses by selecting the socially “harmless” answer ‘suc-
cessful’ to telegraph that they had no particular concerns
in their relationship with the regulatory authority.
Measures
Generally, DGPs obtained a good appraisal, particularly
in terms of readability and contents. As respondents
pointed out, however, they are poorly recognized by the
public; in a survey of 1,707 people who had undergone a
regular physical examination, for example, only 2% had
experienced accessing a DGP and only 15% were in fact
actually aware of them, and an initiative to attract pa-
tient attention to this material is therefore warranted
(Suka 2011). Consistent with the US medication guides,
the scope of drugs requiring the preparation of DPGs is
limited (The US Food and Drug Administration 2011).
However, more than half of respondents supported ex-
tension of the preparation of DGPs to all prescription
drugs, as does the UK Patient Information Leaflet
(Committee on Safety of Medicines 2005). In Japan,
prescription drugs are dispensed with a consumer
medication information (CMI) sheet, which includes a
small picture of the drug in its dosage form and a brief
description of its usage, dosage and adverse reactions.
These are prepared by the dispensing pharmacy, which
primarily sources them from non-authorized drug in-
formation databases maintained by private claims re-
imbursement computer system vendors. In this regard,
a survey of the US CMI sheets reported that thecontents were of low quality, and urged their improve-
ment (Kimberlin and Winterstein 2008; Raynor et al.
2007). In contrast, DGPs provide several pages of rich
and detailed content for patient self-instruction and
are developed by the supplying pharmaceutical com-
pany and reviewed by the regulatory authority at the
expense of national insurance subscribers and patients,
although many are currently in disuse. Utilization of
DGPs as legitimate source documents for the preparation
of CMIs at dispensing pharmacies is strongly recom-
mended. Achieving this will require that all information in
individual DGPs for all prescription drugs become pub-
licly available through an official online database with
easy accessibility using the Standard Generalized Markup
Language.
Our survey respondents also positively noted the effi-
ciency and effectiveness of drug information websites
run by the pharmaceutical companies. Although some
respondents expressed concerned that the information
posted on company-run websites is likely to be partial
and one-sided (Davis et al. 2007), one study reported
that lay people considered that the credibility of infor-
mation on regulatory agency and pharmaceutical com-
pany websites was comparable (Kim 2011). The low
usability of the PMDA website noted in our survey ap-
pears to result from its tangled, multiroute, multistep
path from the home page to target information, and
from the awkwardly organized, overlapping information
and PDF regulatory documents attached to many web-
pages. This should be improved by usability testing from
the perspective of the public, without influence by the
regulatory perspective (Bahri and Harrison-Woolrych
2012b; European Medicines Agency 2013). The signifi-
cance and importance of internet use in searching and
querying drug information was shown in our separate
surveys, which found that 37.4% of community pharma-
cists had utilized company-run websites and that 43% of
people who received regular health checkups had had a
chance to browse for drug information on the Internet
(Suka 2011). The very major importance of official, inte-
grated, and strategic web–based provision of drug infor-
mation should therefore be acknowledged. The EMEA
websites may be referenced as sophisticated examples,
and the EU is also planning to establish a single consoli-
dated online database for drug information (European
Medicines Agency 2013).
The respondents appreciated the significance of direct
communication of risk information by the regulatory
agency, especially in case of emergency. Current Japanese
regulatory advisories, including revision of label informa-
tion, issuance of DHCP letters, and other safety notifica-
tions often require intensive and sometimes contentious
preliminary discussion, followed by tough negotiation be-
fore agreement between the regulatory authority and
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sent the most resource-consuming tasks on both sides.
The risk communication measures implemented by drug
companies under the strict oversight of the regulatory
agency may therefore take considerable time until the
dispatch of key risk messages can proceed, which might in
turn impair the timeliness of risk mitigation actions, and
also compromise the effectiveness and transparency of
communications. Indeed, in July 2011, coincidentally after
the close of this survey, the PMDA launched a new web-
site “On information concerning the risks of drugs under
evaluation” within its “Pharmaceuticals and Medical De-
vices Information Homepage”, similar to the Drug Safety
Communication by the US FDA (Pharmaceuticals and
Food Safety Bureau 2011b; Seligman and Osborne 2009).
Further effective utilization of direct and rapid communi-
cation by the regulatory agency is desirable.
The media were recognized as and expected to play an
essential role in emergency risk communications by the
pharmaceutical company side. This expectation was in
contrast to the lower success rating for communications
targeted to mass media, and the smaller resource alloca-
tion to them. The effectiveness of risk minimization activ-
ities such as DHCP letters is reportedly influenced by
whether the risk receives wide media publicity (Weatherby
et al. 2001; Urushihara et al. 2011; Waller et al. 2006).
However, the legitimate role of the media in risk commu-
nications has been questioned as their interests differ from
those of pharmaceutical companies and regulatory agen-
cies. If the media is conceived of as a public organ of soci-
ety, rather than a private institution that seeks mere
demagoguery and sensation, then its provision of well-
balanced, evidence-based media coverage of safety issues
may be expected to maximize benefits and ameliorate
harms for patients and the public, although admittedly
this remains an ongoing challenge (Bahri 2010; Waller
et al. 2006). The advantage of the UK’s scientific media in
improving the quality of reporting of drug information via
the general media should be acknowledged (Czarnecki
2008; Mebane 2005).
Safety risk management planning was eventually im-
plemented in April 2013 in Japan, following the issuance
of local guidance for risk management plans for pharma-
ceuticals in April 2012, which supplements the ICH E2E
“pharmacovigilance planning” guideline (Pharmaceuti-
cals and Food Safety Bureau 2012). Most global compan-
ies have therefore already experienced the development
and implementation of safety risk management plans,
whereas domestic companies likely have little or no such
experience. More than half of the respondents in this
survey agreed with disclosure of the outlines of risk
management plans, mostly owing to a likely grudging ac-
ceptance of transparency. Disclosure of safety risk man-
agement plans is planned to commence in 2013 and isalso expected to facilitate understanding and cooperation
with practitioners and patients. However, as our respon-
dents noted, tailoring the information to the expected
audience is essential, given its potential to both maximize
the effectiveness of the information and minimize antici-
pated confusion among patients as well as healthcare pro-
fessionals (Bahri and Harrison-Woolrych 2012b).
Limitations
The results of this survey likely represent the partial and
one-sided views of the responding pharmaceutical com-
panies, and comprehensive and impartial investigations
among other important stakeholders should accordingly
follow. Owing to the anonymity of the study process, it
was not possible to identify non-responding companies
and thereby determine the extent of selection bias. The
possibility exists that only those companies which ac-
tively express their opinion on a routine basis dominated
this survey results. This survey did not target generic
drug makers since they generally rely on the marketing
authorization holders of the original drugs and do not
play a central role in risk communication activities. Fur-
ther, the answers derived from the survey may be biased
toward those considered socially desirable, out of con-
cern of criticism after the publication of this survey and
subsequent to internal review within companies before
the answers were returned. Even considering the above
limitations, the high return rate appears sufficient to en-
sure representativeness in Japan, although the results
would not be applicable to companies located in other
countries, which have different medicosocial national
systems.
Conclusions
We conducted a survey to better understand current
risk communications by drug companies located in
Japan. Risk communications operate at two levels, to the
individual patient and to the general public. For both
levels, to be successful implementation, credible messa-
ging is necessary not only about risks, but also the
benefit-risk balance of the particular drug as well as its
outcome evaluation. This notion appears to be well ac-
cepted by the pharmaceutical industry in Japan. Direct
communication by the regulatory agency and mobilization
of mass media channels may enhance the speed and ef-
fectiveness of emergency risk communications, but the
utilization and quality control of these communications
appear premature and should be further explored. Internet
websites are heavily utilized to provide risk information by
regulatory agencies, pharmaceutical companies and other
concerned parties, but the current provision of informa-
tion on drug safety is highly disparate, occurring in various
forms at multiple websites. Establishment of a compre-
hensive, integrated website as a ‘one-stop portal’ should
Urushihara et al. SpringerPlus 2014, 3:51 Page 10 of 11
http://www.springerplus.com/content/3/1/51therefore be considered for maintaining transparency and
sufficient circumstantiality. Such a portal would be
complete with a user-oriented guide and be connected
with a single national repository of ‘authorized’ infor-
mation. This would maintain the standardized quality
of and ease of accessibility to information for audi-
ences with varying IT skills. ‘Official’ drug information
storage at a single national repository might facilitate
the transparency of drug information at the population
level, such as in media publicity, and might also satisfy
individual patient needs during consultation at a doc-
tor’s office, as well as in pharmacological training at
dispensing pharmacies.
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